Digital Science is today calling for greater awareness of the impact that a myriad of fast-developing technologies are having on academics and their institutions.
Tulane University will host the Tulane Future of Energy Forum in New Orleans on Nov. 13-15. The forum, which is free and open to the public, will bring together global leaders to discuss innovative strategies for meeting energy demands while transitioning to a lower-carbon future. This year’s theme, Can Energy Pragmatism Secure Our Energy Future?, will focus on practical solutions, featuring high-caliber speakers, cutting-edge research and opportunities to engage with key decision-makers across the energy sector.
In dementia diseases such as Alzheimer's, incorrectly folded proteins accumulate in the brain. Empa researchers have now resolved a particularly active species of protein fibrils with unprecedented precision. The formation of potentially toxic molecules on the surface of protein fibrils was studied from early to late stages spanning over a period of hours.
The research team of Dr. Byeongjin Park and Dr. Sang Bok Lee at the Korea Institute of Materials Science (KIMS), has developed the world's first ultra-thin film composite material capable of absorbing over 99% of electromagnetic waves from various frequency bands (such as 5G/6G, WiFi, and autonomous driving radar) using a single material.
The National University of Singapore (NUS) will be taking a significant leap forward in synthetic biology, leveraging its deep expertise and cutting-edge innovations to usher a new paradigm for green manufacturing, driven by this rapidly evolving field. Over the next six years, the University plans to dedicate substantial resources and efforts – estimated to value around S$120 million (US$90.6 million) - to firmly establish synthetic biology as a foundational pillar of NUS’ innovation ecosystem, driving transformative benefits for Singapore across multiple sectors.
This year’s lectures highlight time and process management for physicians, leveraging networks for clinical research, innovations in endoscopy, kindness-influenced trust and healing, and personal and professional opportunities in Africa.
Gastroenterologists and other GI health care professionals will convene at the Pennsylvania Convention Center in Philadelphia, PA, for the premier clinical gastroenterology event—the American College of Gastroenterology’s 89th Annual Scientific Meeting and Postgraduate Course (ACG 2024).
Dr. Roy-Chaudhury will head up an organization—with nearly 21,000 health professionals representing 140 countries—dedicated to leading the fight against kidney diseases.
Adults aged 35 to 60 are drinking at unprecedented rates, with those who binge drank in high school reporting more past 30-day high-risk drinking in midlife. And this link may be especially strong for women, according to a study just published in Alcohol: Clinical and Experimental Research Health. These trends are particularly concerning as health conditions, and biological processes common with aging put adults in midlife at greater health risk from alcohol use.
El alergista James Tracy, DO (Doctor en Medicina Osteopática), de Omaha, NE, fue instalado como presidente del Colegio Americano de Alergia, Asma e Inmunología (ACAAI) en la Reunión Científica Anual del ACAAI el 27 de octubre en Boston. La alergista Cherie Zachary, MD, de Eagan, Minnesota, fue elegida presidenta electa del ACAAI.
Allergist James Tracy, DO, of Omaha, NE, was installed as president of the American College of Allergy, Asthma and Immunology (ACAAI) at the ACAAI Annual Scientific Meeting on October 27 in Boston. Allergist Cherie Zachary, MD, of Eagan, MN, was elected ACAAI president-elect.
IgA nephropathy is an autoimmune kidney disease, and complement, a component of the innate immune system, plays a role in the condition’s pathogenesis. Investigators have developed and tested a novel gene therapy that enters kidney cells and enables them to block complement activation. The research will be presented at ASN Kidney Week 2024 October 23– 27.
Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients’ kidney function in a phase 2 trial. Investigators now have data from a phase 3 trial with clazakizumab. The findings from the Phase 3 IMAGINE trial, the largest placebo-controlled study in kidney transplant recipients with caAMR, will be presented at ASN Kidney Week 2024 October 23– 27.
For kidney transplant recipients experiencing antibody-mediated rejection, the current standard of care involves removing donor-specific antibodies (DSAs) through plasmapheresis (PLEX)—a procedure that removes antibodies from the plasma portion of the blood. Results from a recent clinical trial reveal that an investigational drug called imlifidase, which cleaves and inactivates the type of antibodies that include DSAs, is more effective than PLEX. The research will be presented at ASN Kidney Week 2024 October 23–27.
The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23–27.
BACKGROUNDMyocardial ischemia-reperfusion injury (MIRI) poses a prevalent challenge in current reperfusion therapies, with an absence of efficacious interventions to address the underlying causes. AIMTo investigate whether the extracellula
The intrinsic heterogeneity of metabolic dysfunction-associated fatty liver disease (MASLD) and the intricate pathogenesis have impeded the advancement and clinical implementation of therapeutic interventions, underscoring the critical dema
Recently, we read a mini-review published by Jeyaraman et al. The article explored the optimal methods for isolating mesenchymal stromal cells from adipose tissue-derived stromal vascular fraction (SVF). Key factors include tissue source, p
The intrinsic heterogeneity of metabolic dysfunction-associated fatty liver disease (MASLD) and the intricate pathogenesis have impeded the advancement and clinical implementation of therapeutic interventions, underscoring the critical dema
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
